Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.54 |
| ▸ | JAK1 | P23458 | 18/20 | 0.54 |
| ▸ | TYK2 | P29597 | 18/20 | 0.54 |
| ▸ | JAK3 | P52333 | 18/20 | 0.54 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12493142 | 0.85 | EPHB3 (0.49) | JAK2JAK1TYK2JAK3EPHB3 | |
| SCHEMBL9923339 | 0.82 | JAK2 (0.58) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL12699179 | 0.82 | JAK2 (0.56) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL11300658 | 0.81 | EPHB3 (0.55) | JAK2JAK1TYK2JAK3EPHB3 | |
| SCHEMBL12493990 | 0.81 | JAK2 (0.54) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL12681815 | 0.80 | EPHB3 (0.48) | JAK2JAK1TYK2JAK3EPHB3 | |
| SCHEMBL9920355 | 0.77 | ALDH1A1 (0.53) | — | |
| SCHEMBL12492975 | 0.74 | TSHR (0.42) | JAK2JAK1TYK2JAK3EPHB3 | |
| SCHEMBL14757926 | 0.74 | JAK2 (0.48) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL1160541 | 0.74 | JAK1 (0.60) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-2685982-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2685982-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-2685981-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2685981-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9221826-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221826-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221826-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| US-8921368-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20140005146-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-02 | — | — | US | disclosed |
| WO-2013033093-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012125886-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125886-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125887-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125887-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011014817-A1 | PYRROLO [1, 2-B] PYRIDAZINE DERIVATIVES AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 10/4885 |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885TYK2 5/4885 |
| US-20140005146-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885TYK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.